Radioembolization with Yttrium-90 resin microspheres in treatment of HCC with or without PVT: Initial Egyptian experience

Background/AimHepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. Radioembolization with yttrium-90 (Y-90) microspheres is a new concept in radiation therapy for HCC. The aim of this study is to evaluate efficacy, side effects, and future direction of Y-90 therapy, using TheraSphere®, in patients with HCC with or without PVT.Patients and methodsForty patients were presented by hepatocellular carcinoma most of them with portal vein thrombosis and were treated with Y-90 resin microspheres (SIR-TeX®).ResultsAt one month after treatment the overall response (complete or partial response) was exhibited by 9% of patients, stable disease exhibited by 80% of patients, progressive disease seen in 11% of patients.ConclusionRadioembolization with Y-90 resin microspheres offers a favorable risk/benefit profile for patients presenting with locally advanced unresectable HCC with or without PVT and good liver function.